Daxor Corporation Common Stock (DXR)

FairStock Score: 57/100 — STEADY

Key Financials

Strengths

• Generates $100,248 in annual free cash flow (0.2% yield on market cap)
• High return on equity of 22.4% demonstrating efficient capital deployment
• Altman Z-Score of 290.0 confirms minimal bankruptcy risk and strong solvency
• Superior net profit margin of 824.3% indicating pricing power and operational efficiency

Concerns

• Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Daxor Corporation Common Stock is a micro-cap healthcare company valued at $59 million. The business generates $26,688 in annual revenue with a 824.3% net margin and $100,248 in free cash flow. From a quality standpoint, Daxor shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and Altman Z-Score of 290.0 confirms fortress-level solvency. On valuation, the stock is deeply undervalued on a P/E basis at 6.5x, with offers a 45% margin of safety vs Graham Number of $18. Our composite FairStock Score of 57/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

The market underappreciates Daxor's consistent 22% ROE at just 7x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $100,248 in annual free cash flow (0.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer